TWI363629B - Substituted pyrimidodiazepines - Google Patents

Substituted pyrimidodiazepines Download PDF

Info

Publication number
TWI363629B
TWI363629B TW097109660A TW97109660A TWI363629B TW I363629 B TWI363629 B TW I363629B TW 097109660 A TW097109660 A TW 097109660A TW 97109660 A TW97109660 A TW 97109660A TW I363629 B TWI363629 B TW I363629B
Authority
TW
Taiwan
Prior art keywords
mol
tetrahydro
methyl
mixture
racemic
Prior art date
Application number
TW097109660A
Other languages
English (en)
Chinese (zh)
Other versions
TW200843781A (en
Inventor
Jianping Cai
Shaoqing Chen
Xin-Jie Chu
Kang Le
Kin-Chun Thomas Luk
Peter Michael Wovkulich
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI363629(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TW200843781A publication Critical patent/TW200843781A/zh
Application granted granted Critical
Publication of TWI363629B publication Critical patent/TWI363629B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW097109660A 2007-03-22 2008-03-19 Substituted pyrimidodiazepines TWI363629B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22

Publications (2)

Publication Number Publication Date
TW200843781A TW200843781A (en) 2008-11-16
TWI363629B true TWI363629B (en) 2012-05-11

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097109660A TWI363629B (en) 2007-03-22 2008-03-19 Substituted pyrimidodiazepines

Country Status (23)

Country Link
US (1) US7517873B2 (enExample)
EP (1) EP2139892B1 (enExample)
JP (1) JP5087640B2 (enExample)
KR (1) KR101157848B1 (enExample)
CN (2) CN102746175B (enExample)
AR (1) AR065794A1 (enExample)
AT (1) ATE524472T1 (enExample)
AU (1) AU2008228303B2 (enExample)
BR (1) BRPI0809088A2 (enExample)
CA (1) CA2680757A1 (enExample)
CL (1) CL2008000785A1 (enExample)
CY (1) CY1112102T1 (enExample)
DK (1) DK2139892T3 (enExample)
ES (1) ES2371832T3 (enExample)
HR (1) HRP20110807T1 (enExample)
IL (1) IL200617A (enExample)
MX (1) MX2009010034A (enExample)
PE (1) PE20120495A1 (enExample)
PL (1) PL2139892T3 (enExample)
PT (1) PT2139892E (enExample)
SI (1) SI2139892T1 (enExample)
TW (1) TWI363629B (enExample)
WO (1) WO2008113711A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461149B2 (en) 2007-08-15 2013-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
CN103122001A (zh) 2007-09-25 2013-05-29 武田药品工业株式会社 Polo样激酶抑制剂
EP2610256B1 (en) * 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
WO2009153197A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
GEAP202213376A (en) 2009-06-17 2022-02-25 Vertex Pharmaceuticals Incorporated Us Inhibitors of influenza viruses replication
EP2477987B1 (en) 2009-09-14 2018-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
CN103492381A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP3670515B1 (en) 2013-03-15 2024-03-06 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
HUE052178T2 (hu) 2013-11-13 2021-04-28 Vertex Pharma Eljárások influenzavírus-replikáció inhibitorainak elõállítására
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
JP6373490B2 (ja) 2014-09-16 2018-08-15 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体モジュレーターを調製する方法
EA201790369A1 (ru) 2014-09-16 2017-10-31 Джилид Сайэнс, Инк. Твердые формы модулятора толл-подобного рецептора
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
WO2017177092A1 (en) * 2016-04-07 2017-10-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders
EP4034132B1 (en) * 2019-09-27 2026-02-25 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
EP3911654A4 (en) * 2020-03-27 2022-05-11 Uppthera PLK1 SELECTIVE DEGRADATION-INDUCING COMPOUND
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
WO2023017442A1 (en) * 2021-08-10 2023-02-16 Uppthera, Inc. Novel plk1 degradation inducing compound
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2299434T3 (es) * 1999-09-17 2008-06-01 ABBOTT GMBH & CO. KG Inhibidores de kinasa utilizados como agentes terapeuticos.
EP1427730B1 (de) * 2001-09-04 2006-07-12 Boehringer Ingelheim Pharma GmbH & Co.KG Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
CA2652648C (en) * 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
ES2371832T3 (es) 2012-01-10
IL200617A (en) 2014-02-27
AU2008228303A1 (en) 2008-09-25
HRP20110807T1 (hr) 2011-12-31
CA2680757A1 (en) 2008-09-25
WO2008113711A1 (en) 2008-09-25
BRPI0809088A2 (pt) 2014-09-09
US20080234255A1 (en) 2008-09-25
EP2139892B1 (en) 2011-09-14
CY1112102T1 (el) 2015-11-04
PT2139892E (pt) 2011-11-21
CL2008000785A1 (es) 2009-03-27
MX2009010034A (es) 2009-10-12
PL2139892T3 (pl) 2012-03-30
CN101636399A (zh) 2010-01-27
CN102746175A (zh) 2012-10-24
AU2008228303B2 (en) 2012-04-19
PE20120495A1 (es) 2012-05-12
JP5087640B2 (ja) 2012-12-05
US7517873B2 (en) 2009-04-14
TW200843781A (en) 2008-11-16
JP2010521514A (ja) 2010-06-24
HK1139936A1 (en) 2010-09-30
CN102746175B (zh) 2014-01-15
ATE524472T1 (de) 2011-09-15
EP2139892A1 (en) 2010-01-06
SI2139892T1 (sl) 2011-12-30
KR101157848B1 (ko) 2012-07-11
CN101636399B (zh) 2012-04-18
AR065794A1 (es) 2009-07-01
DK2139892T3 (da) 2011-12-12
KR20090119913A (ko) 2009-11-20
IL200617A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
TWI363629B (en) Substituted pyrimidodiazepines
TWI710552B (zh) 作為神經元組織胺受體-3拮抗劑之化合物及其用途
ES2286491T3 (es) Piperidina-ftalazonas sustituidas con pirrolidinadiona, como agentes inhibidores de la pde4.
KR101766194B1 (ko) RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
JP5609861B2 (ja) キノキサリン化合物
TW202417450A (zh) 三環化合物及其用途
US8318731B2 (en) Pyrrolopyrimidines
TW200918074A (en) Substituted piperidino-dihydrothienopyrimidines
TW201242965A (en) Ring-fused heterocyclic derivative
TW200520758A (en) Novel pharmaceuticals
TW200908959A (en) Tetrahydropyranochromene gamma secretase inhibitors
CN104987324A (zh) 作为alk抑制剂的嘧啶衍生物
TW200901994A (en) Spiroindolinone derivatives
CN115785068A (zh) Kif18a抑制剂
EP3768272B1 (en) Jak inhibitors
WO2023041055A1 (zh) Kif18a抑制剂
WO2004043959A1 (ja) 新規parp阻害剤
EP3202767A1 (en) Azabicyclo derivatives, process for preparation thereof and medical use thereof
AU2014231722A1 (en) Salts, co-crystals, and polymorphs of an anxiolytic compound
TW201202248A (en) 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof
TW200800194A (en) Kinase inhibitors
WO2023025244A1 (zh) Sarm1酶活性抑制剂及其应用
WO2011136192A1 (ja) イミダゾ[1,2-a]ピリジン誘導体
WO2025247067A1 (zh) Kif18A抑制剂
HK40109178A (zh) 酪氨酸激酶抑制剂

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees